Diuretic
PreclinicalSmall molecule
Diuretic is one of 71 small molecule programs targeting Breast Cancer. It is currently in Preclinical.
4
Indications
7
Total Trials
1
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
706 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Lexiscan
AstellasPreclinical
Zolymbus
AbbViePreclinical
Blenoxane
Bristol-Myers SquibbPreclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Spravato
WWim Janssens
Preclinical
Sporanox
SSebela Pharmaceuticals Development LLC
Preclinical
Acupan
YYonsei University
Preclinical
Chantix
PPrism Pharmaceuticals
Preclinical
Nubain
AAultman Health Foundation
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Heart Failure1 trial
Breast Cancer1 trial
Long-term Use of CCB and Breast Cancer Risk
Active, not recruiting·—··NCT05972785·68,500 enrolled
Refractory1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Diuretic. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- RReprieve Cardiovascular, Inc